

TABLE 193: NEUTROPENIA/THROMBOCYTOPENIA

AUTHOR, YEAR, STUDY NAME	GENOTYPE	TREATMENT	NEUTROPENIA			THROMBOCYTOPENIA		
			n	N	%	n	N	%
Afdhal et al., 2014 ION-1	1	(6) SOF12 + LDV12	1	214	0%	1	214	0%
		(7) SOF24 + LDV24	3	217	1%	1	217	0%
		(10) SOF12 + LDV12 + RBV12	0	217	0%	0	217	0%
		(11) SOF24 + LDV24 + RBV24	0	217	0%	0	217	0%
Fried et al., 2013 PILLAR	1	(1) PR48	16	77	21%	NR		
		(42) SIM12 PR24-48 RGT	19	77	25%			
Gane et al., 2013-1 ELECTRON	2+3	(3) SOF12 + RBV12	0	10	0%	NR		
		(40) SOF12 + PR12	2	11	18%			
Gane et al., 2013-3 ELECTRON	1	(3) SOF12 + RBV12	0	25	0%	NR		
Gane et al., 2014-1 ELECTRON	1	(10) SOF12 + LDV12 + RBV12	0	25	0%	NR		
Jacobson et al., 2011 ADVANCE	1	(1) PR48	68	361	19%	NR		
		(32) T12 PR24-48 RGT q8	51	363	14%			
Jacobson et al., 2014 QUEST-1	1	(1) PR48	23	130	18%	5	130	4%
		(42) SIM12 PR24-48 RGT	64	264	24%	18	264	7%
Kowdley et al., 2013 ATOMIC	1	(40) SOF12 + PR12	12	52	23%	5	52	10%
Lawitz et al., 2013 NEUTRINO	1+4+5+6	(40) SOF12 + PR12	NR			7	327	2%
Lawitz et al., 2013 FISSION	2+3	(3) SOF12 + RBV12	0	256	0%	0	256	0%

AUTHOR, YEAR, STUDY NAME	GENOTYPE	TREATMENT	NEUTROPENIA			THROMBOCYTOPENIA		
			n	N	%	n	N	%
		(70) PR24	30	243	12%	5	243	2%
Lawitz et al., 2013-1 PROTON	1	(1) PR48	5	26	19%	NR		
		(41) SOF12 PR24-48 RGT	14	47	30%			
Lawitz et al., 2013-2 PROTON	2+3	(40) SOF12 + PR12	6	25	24%	NR		
Manns et al., 2014 HALLMARK-DUAL	1b	(17) DCV24 + ASU24	0	205	0%	NR		
Manns et al., 2014 QUEST-2	1	(1) PR48	36	134	27%	9	134	7%
		(42) SIM12 PR24-48 RGT	54	257	21%	13	257	5%
Marcellin et al., 2011	1	(32) T12 PR24-48 RGT q8	4	82	5%	NR		
		(33) T12 PR24-48 RGT q12	1	79	1%			
Osinusi et al., 2013 SPARE-1	1	(4) SOF24 + RBV24	0	10	0%	NR		
Osinusi et al., 2013 SPARE-2	1	(4) SOF24 + RBV24	0	25	0%	NR		
		(71) SOF24 + RBV (low dose) 24	1	25	4%			
Osinusi et al., 2015	1	(6) SOF12 + LDV12	1	50	2%	NR		
Poordad et al., 2011 SPRINT2	1	(1) PR48	77	363	21%	NR		
		(46) B24 PR28-48 RGT	92	368	25%			
Rodriguez-Torres et al., 2015	1+2+3+4	(40) SOF12 + PR12	4	23	17%	4	23	17%
Sulkowski et al., 2013	1	(1) PR48	2	34	6%	0	34	0%
		(50) B44 PR48	12	64	19%	5	64	8%
Sulkowski et al., 2013-1+2 ^a	1	(1) PR48	5	22	23%	0	22	0%
		(39) T12 PR48 q8	9	38	24%	1	38	3%
Zeuzem et al., 2015-1+2+3 C-EDGE	1+4+6	(22) GRZ12 + ELB12	39	316	12%	NR		

ASU = asunaprevir; B = boceprevir; BEC = beclabuvir; b.i.d. = twice daily; CrI = credible interval; DAS = dasabuvir; DCV = daclatasvir; ELB = elbasvir; GRZ = grazoprevir; LDV = ledipasvir; NR = not reported; OMB = ombitasvir; PAR = paritaprevir; PR = pegylated interferon plus ribavirin; q8 = every 8 hours; q12 = every 12 hours; RBV = ribavirin; RD = risk difference; RGT = response-guided therapy; RIT = ritonavir; RR = relative risk; SIM = simeprevir; SOF = sofosbuvir; T = telaprevir; vs. = versus.

Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.

^a Data for ineligible participants who receive efavirenz-based antiretroviral and 1,125 mg of telaprevir every 8 hours are also included.